Smith Pharmaceutical's has two products whose exclusive patents will be expiring in January, 2022. These two products produce $10,000,000 of revenue annually. Smith has managed earnings in recent years by decreasing research and development expenditures and as a result it will be at least 3 years before any new medicines developed by Smith will be approved by the FDA and be available to consumers. What impact will this have on your assessment of the earnings quality for the year ending December 31, 2021? Question 29 options: a) Earnings quality will be weaker due to sustainability issues b) Earnings quality will be weaker to to substance issues c) Earnings quality will be stronger due to substance issues. d) Earnings quality will be stronger due to sustainability issues
Smith Pharmaceutical's has two products whose exclusive patents will be expiring in January, 2022. These two products produce $10,000,000 of revenue annually. Smith has managed earnings in recent years by decreasing research and development expenditures and as a result it will be at least 3 years before any new medicines developed by Smith will be approved by the FDA and be available to consumers.
What impact will this have on your assessment of the earnings quality for the year ending December 31, 2021?
Question 29 options:
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
